Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Commentary|Articles|August 4, 2026
OS Wins, New Approvals, and Practice-Changing Data: Breaking Down the Biggest NSCLC News From ASCO 2026
Author(s)Caroline Seymour
Fact checked by: Kyle Doherty
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.
Advertisement
Advertisement
As data emerged across the non–small cell lung cancer (NSCLC) space at the
Related to this article
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
Thoracic oncologists discuss HER2 testing, frontline treatment selection, and resistance mechanisms in HER2-altered non–small cell lung cancer.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Experts break down key gastrointestinal cancer data and trends from the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Advertisement
Advertisement